Current and future antifungal therapy: new targets for antifungal therapy.
Invasive fungal infections will continue to cause major complications in immunocompromized patients. At the moment, the expansion of antifungal drug research has occurred because there is a critical need for new antifungal agents to treat these life-threatening invasive fungal infections. The overview of the development of antifungal therapy which is provided here demonstrates the increased interest in this very special area of infectious diseases. Although we now have some newer and less toxic antifungal agents that are currently available for clinical use, their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not very good. Intense efforts in antifungal drug discovery are urgently needed to develop more promising and effective antifungal agents for use in the clinical arena.
Andriole
V T
VT
Yale University, School of Medicine, 333 Cedar Street, 201 LCI, New Haven, CT 06518, USA. andriolevt@masp03.mas.yale.edu
D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D005544:Forecasting; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000188:drug therapy*; D009705:Nucleosides / Q000494:pharmacology / Q000627:therapeutic use*; D011090:Polyenes / Q000494:pharmacology / Q000627:therapeutic use*
D000935:Antifungal Agents; D009705:Nucleosides; D011090:Polyenes